VACCITECH PLC (VACC) Stock Price & Overview
NASDAQ:VACC • US91864C1071
Current stock price
The current stock price of VACC is 5 USD. Today VACC is up by 11.36%. In the past month the price increased by 47.06%. In the past year, price increased by 116.45%.
VACC Key Statistics
- Market Cap
- 192.733M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.45
- Dividend Yield
- N/A
VACC Stock Performance
VACC Stock Chart
VACC Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VACC. When comparing the yearly performance of all stocks, VACC is one of the better performing stocks in the market, outperforming 99.36% of all stocks.
VACC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VACC. No worries on liquidiy or solvency for VACC as it has an excellent financial health rating, but there are worries on the profitability.
VACC Earnings
VACC Forecast & Estimates
11 analysts have analysed VACC and the average price target is 9.5 USD. This implies a price increase of 89.97% is expected in the next year compared to the current price of 5.
For the next year, analysts expect an EPS growth of -1733.53% and a revenue growth -95.74% for VACC
VACC Financial Highlights
Over the last trailing twelve months VACC reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS decreased by -4723.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.32% | ||
| ROE | -25.29% | ||
| Debt/Equity | 0 |
VACC Ownership
VACC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VACC
Company Profile
Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmunity. The company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The company has a pipeline of both clinical and preclinical-stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB); VTP-200 for the treatment of human papilloma virus infection (HPV); VTP-850 for the treatment of prostate cancer; VTP-600 for the treatment of non-small cell lung cancer (NSCLC); VTP-1000 for the treatment of celiac disease, and VTP-1100 for the treatment of HPV-associated cancers. Its prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles, and VTP-500 for the prevention of Middle East respiratory syndrome (MERS).
Company Info
IPO: 2021-04-30
VACCITECH PLC
Unit 6-10, Zeus Building, Rutherford Avenue, Harwell
Didcot OXFORDSHIRE OX4 4GE GB
CEO: William Enright
Employees: 107
Phone: 4401865818808.0
VACCITECH PLC / VACC FAQ
What does VACC do?
Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmunity. The company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The company has a pipeline of both clinical and preclinical-stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB); VTP-200 for the treatment of human papilloma virus infection (HPV); VTP-850 for the treatment of prostate cancer; VTP-600 for the treatment of non-small cell lung cancer (NSCLC); VTP-1000 for the treatment of celiac disease, and VTP-1100 for the treatment of HPV-associated cancers. Its prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles, and VTP-500 for the prevention of Middle East respiratory syndrome (MERS).
What is the current price of VACC stock?
The current stock price of VACC is 5 USD. The price increased by 11.36% in the last trading session.
Does VACCITECH PLC pay dividends?
VACC does not pay a dividend.
What is the ChartMill technical and fundamental rating of VACC stock?
VACC has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for VACC stock?
The Revenue of VACCITECH PLC (VACC) is expected to decline by -95.74% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is VACCITECH PLC worth?
VACCITECH PLC (VACC) has a market capitalization of 192.73M USD. This makes VACC a Micro Cap stock.